Incyte acquires global rights to MorphoSys’ tafasitamab

Incyte has acquired sole worldwide rights to tafasitamab immunotherapy through an asset purchase agreement with MorphoSys.

Feb 6, 2024 - 18:00

Incyte acquires global rights to MorphoSys’ tafasitamab

Incyte has acquired sole worldwide rights to tafasitamab immunotherapy through an asset purchase agreement with MorphoSys.

Read the original article

Tags:

Previous Article

Silence announces $120m private placement for depositary shares

Risk adjusted net present value: What is the current valuation of Caribou Biosci...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Angelini gets grant for method for labelling reels usin...

Mar 30, 2024

STAT+: Pharmalittle: Eisai executive to retire; Express Scripts adds three Humira biosimilars to formulary

STAT+: Pharmalittle: Eisai executive to retire; Express...

Jul 12, 2023

Vorolanib by EyePoint Pharmaceuticals for Diabetic Macu...

Feb 8, 2024